9 7 4 9 1
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
已发表论文
miR-544A 通过靶向钙黏素 1 促进体外肺癌细胞侵袭
Authors Mo X, Zhang F, Liang H, Liu M, Li H, Xia H
Published Date June 2014 Volume 2014:7 Pages 895—900
DOI http://dx.doi.org/10.2147/OTT.S61695
Received 1 February 2014, Accepted 17 March 2014, Published 4 June 2014
Objective: To find out the effect of miR-544a on the invasion of lung cancer cells and to explore the underlying molecular mechanisms.
Methods: Micro-ribonucleic acid (miRNA) expression in two different invasive lung cancer cell lines 95C (low invasive ability) and 95D (high invasive ability) was analyzed by miRNA microarray and real-time quantitative polymerase chain reaction (PCR); miR-544a mimic was transfected to 95C, and its invasion ability was detected by transwell migration assay; we predicted the candidate miRNA target genes by TargetScan (Whitehead Institute for Biomedical Research, Cambridge, MA, USA) software and verified the target genes by Western blot.
Results: The expression of miR-544a was significantly increased in 95D in miRNA microarray and quantitative PCR tests (P <0.05). After being transfected with miR-544a mimic, the invasion ability of 95C was enhanced (P <0.01). Moreover, transfection with miR-544a inhibitor decreased the invasion ability of 95D (P <0.01). miR-544a possibly combined with CDH1 (E-cadherin) predicted by the TargetScan analysis. 95C with miR-544a mimic reduced the expression of CDH1 and improved the expression of vimentin, while 95D with miR-544a inhibitor improved the expression of CDH1 and reduced the expression of vimentin.
Methods: Micro-ribonucleic acid (miRNA) expression in two different invasive lung cancer cell lines 95C (low invasive ability) and 95D (high invasive ability) was analyzed by miRNA microarray and real-time quantitative polymerase chain reaction (PCR); miR-544a mimic was transfected to 95C, and its invasion ability was detected by transwell migration assay; we predicted the candidate miRNA target genes by TargetScan (Whitehead Institute for Biomedical Research, Cambridge, MA, USA) software and verified the target genes by Western blot.
Results: The expression of miR-544a was significantly increased in 95D in miRNA microarray and quantitative PCR tests (P <0.05). After being transfected with miR-544a mimic, the invasion ability of 95C was enhanced (P <0.01). Moreover, transfection with miR-544a inhibitor decreased the invasion ability of 95D (P <0.01). miR-544a possibly combined with CDH1 (E-cadherin) predicted by the TargetScan analysis. 95C with miR-544a mimic reduced the expression of CDH1 and improved the expression of vimentin, while 95D with miR-544a inhibitor improved the expression of CDH1 and reduced the expression of vimentin.
Conclusion: miR-544a can promote the invasion of non-small cell lung cancer by downregulation of CDH1 and upregulation of vimentin.
Keywords: NSCLC, non-small cell lung cancer, E-cadherin, microRNA, EMT
